Literature DB >> 17846977

Acute glucose fluctuations and chronic sustained hyperglycemia as risk factors for cardiovascular diseases in patients with type 2 diabetes.

C Colette1, L Monnier.   

Abstract

Chronic hyperglycemia, usually assessed from HbA1c determinations, results in excessive glycation and generation of oxidative stress. As a consequence, chronic hyperglycemia has been identified as a risk factor for diabetes complications leading to accelerated atherosclerosis. Both fasting and postprandial hyperglycemia contribute to this process. However the acute glucose fluctuations that occur in diabetes have been recently described as an additional factor that activates the oxidative stress. As a consequence, acute glucose swings, including upward (postprandial) and downward (interprandial) fluctuations can be considered as risk factors for cardiovascular events and should be included in the "dysglycemia" of diabetes in combination with fasting and postprandial hyperglycemia. As postprandial glucose is a contributor of both acute glucose fluctuations and chronic sustained hyperglycemia, it remains difficult to know whether these 2 mechanisms are equivalent or not equivalent risk factors for cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17846977     DOI: 10.1055/s-2007-985157

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  19 in total

1.  Glycemic variability: the third component of the dysglycemia in diabetes. Is it important? How to measure it?

Authors:  Louis Monnier; Claude Colette; David R Owens
Journal:  J Diabetes Sci Technol       Date:  2008-11

2.  Improved post-prandial ghrelin response by nateglinide or acarbose therapy contributes to glucose stability in Type 2 diabetic patients.

Authors:  F Zheng; X Yin; W Lu; J Zhou; H Yuan; H Li
Journal:  J Endocrinol Invest       Date:  2013-01-14       Impact factor: 4.256

Review 3.  Metabolic syndrome, aging and involvement of oxidative stress.

Authors:  Francesca Bonomini; Luigi Fabrizio Rodella; Rita Rezzani
Journal:  Aging Dis       Date:  2015-03-10       Impact factor: 6.745

4.  Periodic vs constant high glucose in inducing pro-inflammatory cytokine expression in human coronary artery endothelial cells.

Authors:  Tingsong Liu; Jianbin Gong; Yitian Chen; Shisen Jiang
Journal:  Inflamm Res       Date:  2013-04-27       Impact factor: 4.575

5.  Diabetes and biomarkers.

Authors:  Erica J Caveney; Oren J Cohen
Journal:  J Diabetes Sci Technol       Date:  2011-01-01

6.  t-Resveratrol Protects against Acute High Glucose Damage in Endothelial Cells.

Authors:  Leda Guzmán; Cristóbal Balada; Guillermo Flores; Rocío Álvarez; Marcela Knox; Raúl Vinet; José L Martínez
Journal:  Plant Foods Hum Nutr       Date:  2018-09       Impact factor: 3.921

7.  Glucose-modulated tyrosine nitration in beta cells: targets and consequences.

Authors:  Thomas Koeck; John A Corbett; John W Crabb; Dennis J Stuehr; Kulwant S Aulak
Journal:  Arch Biochem Biophys       Date:  2009-04-15       Impact factor: 4.013

8.  Targeting prandial hyperglycemia: how important is it and how best to do this?

Authors:  Louis Monnier; Claude Colette
Journal:  Curr Diab Rep       Date:  2008-10       Impact factor: 4.810

9.  Association of glycaemic variability evaluated by continuous glucose monitoring with diabetic peripheral neuropathy in type 2 diabetic patients.

Authors:  Yu-Ming Hu; Li-Hua Zhao; Xiu-Lin Zhang; Hong-Li Cai; Hai-Yan Huang; Feng Xu; Tong Chen; Xue-Qin Wang; Ai-Song Guo; Jian-An Li; Jian-Bin Su
Journal:  Endocrine       Date:  2018-02-06       Impact factor: 3.633

10.  Lack of correlation between the optimal glycaemic control and coronary micro vascular dysfunction in patients with diabetes mellitus: a cross sectional study.

Authors:  Luis Felipe Valenzuela-Garcia; Yasushi Matsuzawa; Jaskanwal D S Sara; Taek-Geun Kwon; Ryan J Lennon; Lilach O Lerman; Rafael J Ruiz-Salmeron; Amir Lerman
Journal:  Cardiovasc Diabetol       Date:  2015-08-14       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.